Emergent BioSolutions | EBS - Ativos





Ativos Alterar Data
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
ALKERMES USD 4.26B 1.77B 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
ANI Pharmaceuticals USD 1.44B 32.22M 2025-12
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Exelixis USD 2.84B 20.87M 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
Lexicon Pharmaceuticals USD 184.99M 20.94M 2025-12
Lonza CHF 18.97B 164M 2025-12
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Myriad Genetics USD 706.6M 21.5M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pacira USD 1.21B 56.38M 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.9B 255.07M 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Xoma USD 263.15M 39.7M 2025-09